Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma

DBCOND0159375Hematologic Neoplasms

Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as: Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Classified under: Hematologic Neoplasms
Indicated drugs: Polatuzumab vedotin

What you can answer from here — as of October 23, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

1Structured indicationPopulation, line of therapy, route and combination as fields, not prose

2Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account